Our group has previously demonstrated that B7-H3 silencing conferred reduced metastatic capacity and increased chemosensitivity in both in vitro and in vivo models [23–25], implying that B7-H3 is involved in cancer progression also via non-immunological mechanisms. This evidence concerns the gene CD276 and cancer.